CAMBRIDGE, Mass. — Biotech company Genzyme is selling its diagnostics business to Sekisui Chemical for $265 million, Genzyme said Thursday.
Under the deal, Sekisui will purchase the diagnostics business’ assets, including product lines and technologies, and offer employment to its 575 employees while maintaining operations in all of its current locations.
